Plant Name: Sesamum indicum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; HRH1; ADORA2A; ADORA1; HCAR2; HTR2B; | |
| NPSR1; | |
| TDP1; ALPI; FAAH; RECQL; CDA; ADK; TERT; AKR1B1; POLB; | |
| GAA; ACHE; | |
| KCNH2; | |
| PRKCA; | |
| CA2; CA12; CA1; CA9; CA14; CA7; CA5A; CA6; | |
| NR1I2; | |
| PPARA; PPARD; PPARG; | |
| NR1H4; | |
| KDM4E; | |
| STAT6; | |
| SLC6A15; SLC28A2; SLC28A3; SLC28A1; | |
| HTT; LMNA; FABP5; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| SLC superfamily of solute carriers | SLC6A15 | Sodium-dependent neutral amino acid transporter B(0)AT2 | Q9H2J7 | CHEMBL3351189 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.849E-13 | 1.955E-09 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.963E-12 | 1.438E-08 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.391E-11 | 1.788E-07 | CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.935E-10 | 1.292E-06 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.151E-09 | 1.791E-06 | ALPI, CA1, CA12, CA2, CA5A, CA6, CA7, CA9, CDA, NR1H4, NR1I2, PPARA, PPARD, PPARG, PRKCA |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.254E-08 | 1.606E-05 | AKR1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NR1H4, NR1I2, PPARD |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.936E-08 | 2.108E-05 | CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.516E-08 | 5.912E-05 | CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.069E-07 | 9.314E-05 | CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.656E-07 | 1.336E-04 | NR1H4, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 4.264E-07 | 2.995E-04 | NR1H4, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.760E-07 | 3.239E-04 | CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NR1I2 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 5.670E-07 | 3.337E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.024E-06 | 5.184E-04 | ADORA1, ADORA2A, CA2, CA7, HTR2B, HTT, NPSR1 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.356E-06 | 6.419E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.781E-06 | 8.253E-04 | ADORA2A, CA2, CA7, HCAR2, HTT, NPSR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.934E-06 | 8.771E-04 | CYP2C19, CYP2C8, CYP2C9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.119E-06 | 1.358E-03 | ADORA1, ADORA2A, CA2, CA7, HCAR2, HTR2B, HTT, NPSR1, NR1H4 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 4.583E-06 | 1.856E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0032501; multicellular organismal process | GO:0044057; regulation of system process | 6.398E-06 | 2.167E-03 | ADORA1, ADORA2A, ADORA3, GAA, HCAR2, HRH1, KCNH2, LMNA, PRKCA |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 6.567E-06 | 2.167E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 6.567E-06 | 2.167E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 6.567E-06 | 2.167E-03 | SLC28A2, SLC28A3 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 8.925E-06 | 2.699E-03 | ADORA1, ADORA2A, MAPT |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.082E-05 | 3.099E-03 | CYP2C19, CYP2C8, CYP2C9 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.690E-05 | 4.601E-03 | ADORA1, ADORA2A, HRH1, HTR2B, PPARD |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.967E-05 | 4.716E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.967E-05 | 4.716E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.967E-05 | 4.716E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.967E-05 | 4.716E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.971E-05 | 4.716E-03 | CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.967E-05 | 4.716E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.100E-05 | 4.971E-03 | CYP2C19, CYP2C8, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 2.124E-05 | 4.974E-03 | NR1H4, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.787E-05 | 6.192E-03 | CYP2C8, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 3.090E-05 | 6.728E-03 | ACHE, ADORA2A, HCAR2, HTR2B, NR1H4, PPARD |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.102E-18 | 1.546E-13 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.024E-17 | 2.287E-15 | CA12; CA1; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.504E-07 | 1.980E-05 | CYP2C9; CYP2C8; CYP2D6; HTR2B; PRKCA; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.923E-07 | 2.238E-05 | CYP2C9; CYP2C8; CYP2D6; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.838E-07 | 2.238E-05 | CYP2C9; CYP2C8; CYP3A4; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.651E-05 | 5.990E-04 | FABP5; PPARG; PPARA; PPARD |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.236E-05 | 9.861E-04 | CYP2C9; CYP2C8; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.012E-04 | 7.857E-03 | CYP2C9; CYP2C8; CYP2C19 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 6.258E-04 | 7.857E-03 | HRH1; ADORA2A; ADORA3; ADORA1; HTR2B |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.758E-04 | 7.857E-03 | CYP2C9; CYP2C8; CYP3A4 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.058E-03 | 9.963E-03 | HRH1; ADORA2A; HTR2B; PRKCA |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.085E-04 | 8.305E-03 | CYP2C9; CYP2D6; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.532E-03 | 1.331E-02 | HCAR2; ADORA2A; ADORA1; PPARA |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.455E-04 | 8.305E-03 | CA2; NR1H4; CYP3A4 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.892E-03 | 1.527E-02 | HRH1; HTR2B; PRKCA |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.266E-03 | 2.235E-02 | CYP2C9; CDA; CYP2C8; GAA; ADK; AKR1B1; ALPI; CYP2C19; CYP3A4 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.362E-03 | 2.235E-02 | ADORA3; ADORA1; PRKCA |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.910E-03 | 3.710E-02 | CDA; CYP3A4 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.548E-03 | 1.919E-02 | GAA; AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HRH1; HRH1; HRH1; CYP3A4; ACHE; FAAH |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| NA: NA | Hypersensitivity reactions | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2; ADORA1; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; HRH1; HRH1; CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| NA: NA | Itching | NA | HRH1 |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; HRH1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | HRH1; HRH1; HRH1; HRH1; HRH1; ADORA2A |
| NA: NA | Allergic disorders | NA | HRH1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | HRH1; HRH1; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HRH1; ADORA2A; ADORA1; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HRH1; ADORA2A; ADK; ACHE; FAAH |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |
| NA: NA | Vertigo's disease | NA | HRH1 |
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; HRH1 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | HRH1 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1 |
| NA: NA | Respiratory allergies | NA | HRH1; HRH1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| NA: NA | Urticaria | NA | HRH1; HRH1; HRH1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HRH1; PPARD; PPARD; PPARG |
| NA: NA | Meniere's disease | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; AKR1B1; PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; HRH1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HCAR2; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; HRH1; CA1; CA9; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1; FAAH |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CDA; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | HRH1; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2; ADORA2A |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; PPARD; NR1I2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| NA: NA | Common cold | NA | HRH1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B; CYP2D6 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HRH1; HRH1 |
| NA: NA | Morning sickness | NA | HRH1 |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; HRH1; HRH1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HRH1; HTR2B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1 |
| NA: NA | Coughs | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Vasomotor rhinitis | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| NA: NA | Vomiting | NA | HRH1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1; AKR1B1; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; FAAH |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1 |